Eli Lilly and Co. plans to set up a $31 million digital health innovation hub in Singapore, expanding its research and ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...

While Mounjaro and Zepbound are Eli Lilly and Company's leading growth ... in late 2027 and will increase the company's exposure to Lebanon, Indiana, to more than $13 billion.

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

Upon a comprehensive analysis of Eli Lilly, the following trends can be discerned: The Price to Earnings ratio of 112.95 for this company is 4.17x above the industry average, indicating a premium ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks with consistent growth to buy. Currently, financial markets are experiencing a ...

dividend-frequency { font-size: 12px; color: #6c757d; } Through an analysis of Eli Lilly, we can infer the following trends: At 86.87, the stock's Price to Earnings ratio significantly exceeds the ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...